Compare CKX & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CKX | CMMB |
|---|---|---|
| Founded | 1930 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5M | 19.9M |
| IPO Year | 1996 | 2023 |
| Metric | CKX | CMMB |
|---|---|---|
| Price | $11.12 | $2.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 3.8K | ★ 98.2K |
| Earning Date | 05-11-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1125.00 | 101.67 |
| EPS | ★ 0.09 | 0.04 |
| Revenue | ★ $838,543.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $123.56 | ★ $67.75 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.66 | $1.35 |
| 52 Week High | $13.00 | $3.55 |
| Indicator | CKX | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 47.59 | 84.13 |
| Support Level | $10.23 | $1.47 |
| Resistance Level | $10.78 | $2.86 |
| Average True Range (ATR) | 0.37 | 0.21 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 27.93 | 87.54 |
CKX Lands Inc is a Louisiana corporation organized to receive non-producing mineral royalties spun off by a southwest Louisiana bank. It operates in three segments: Oil and Gas, Surface, and Timber. The company owns land and mineral interests and collects income through its ownership of oil and gas royalties, surface leases for farming, the right of way, and other uses, and timber sales. The company's oil and gas royalties are paid by the operators who own the wells, and timber income is paid by the highest bidder for the timber. It has small royalty interests in approximately 20 different producing oil and gas fields. Maximum revenue for the company is generated from the Timber segment.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.